We have injected purified Staphylococcus aureus protein A intraperitoneally into leukemic cats infected with feline leukemia virus, into cats persistently infected with feline leukemia virus but without hematologic or cytologic abnormalities, and into healthy cats without feline leukemia virus infection. Pre-and post-treatment serum samples were evaluated sequentially for interferon activity and for complement-dependent cytotoxic antibody. Our results indicate that serum interferon increased dramatically (<3 to 324 units/ml) during treatment only in cats that responded to staphylococcal protein A therapy. Increase of interferon preceded or was closely associated with increasing levels of cytotoxic antibody, loss of viremia, and correction of cytological and hematological abnormalities of three leukemic cats. The cytotoxic antibody was shown to be specific for envelope glycoprotein gp7O of the feline leukemia virus. One persistently feline leukemia virus-infected cat without leukemia that became nonviremic also developed high levels of interferon and specific cytotoxic antibody. By contrast, interferon levels of cats not responding to treatment had levels of <3 to 27 units/ml. Normal healthy cats injected with staphylococcal protein A showed moderate transient increases of interferon but no detectable cytotoxic antibodies to FL-74 cells. These data suggest that interferon and cytotoxic antibody may play important, possibly complementary roles in inducing remission of leukemia and loss of viremia in cats treated with staphylococcal protein A.Remission of leukemia-lymphoma associated with disappearance of feline leukemia virus (FeLV) (4,5), IFN activity and complementdependent cytotoxic antibody were studied in sera of several cats that had been injected i.p. with SPA. It will be shown that regression of malignancy and loss of evidence of virus infection occurred in cats that experienced first an increase in IFN that was followed by appearance and usually progressive increase of a complement-dependent cytotoxic antibody directed against a virus-infected feline lymphoma cell line.
MATERIAL AND METHODSAnimals. Pet cats were selected for treatment by ex vivo immunoadsorption (2, 3) or by injection with purified SPA (Pharmacia, Uppsala, Sweden). The SPA injections were given i.p. (20 pug/2.75 kg of body weight) twice weekly for 10-12 weeks. Bone marrow and peripheral blood smears were evaluated prior to treatments and after every 10th treatment. FeLV status was determined biweekly by indirect immunofluorescence assay (IFA) (6) and enzyme-linked immunosorbent assay (ELISA) as described (2). Pre-and posttreatment serum samples were stored at -70'C until assayed for IFN and cytotoxic antibody.Feline IFN Assay. Feline IFN was assayed by a modification of the microplaque reduction method (7), using approximately 40 plaque-forming units (pfu) of vesicular stomatitis virus (VSV) per well on FFC-9 cells (fetal cat fibroblast cell line kindly provided by N. C. Pedersen, University of California, Davis). An IFN concen...